SPOTLIGHT -
Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.
FDA accepts IND application for RAG-01 in NMIBC
The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Dr. Matin discusses early work with FGFR inhibition in localized UTUC
"And [3 out of 5] of those patients who were initially deemed to go on to nephroureterectomy were able to be converted to endoscopic management," says Surena F. Matin, MD.
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Clinical trial program of nadofaragene firadenovec in NMIBC expands
The 3 new additional studies are the ABLE-22, ABLE-32, and ABLE-42 clinical trials.
FDA accepts IND application for UGN-103 in NMIBC
The IND will initiate the launch of a phase 3 study to explore the safety and efficacy of UGN-103 in patients with low-grade, intermediate-risk NMIBC.